{"schema_version":"secwatch.filing_event.v1","accession":"0000917520-23-000060","form_type":"8-K","ticker":"IART","cik":"0000917520","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.022452+00:00","generated_at":"2026-06-13T01:56:47.963352+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Integra Q2 adj EPS $0.71, revenue $381M (-4.2%); FDA warning on Boston facility; guides down","bullets":["Q2 GAAP diluted EPS $0.05 vs $0.54; adjusted EPS $0.71 vs $0.82; revenue $381.3M declined 4.2% reported, 2.7% organic.","Codman Specialty Surgical organic growth 6.3%; Tissue Technologies organic decline 19.7% due to Boston recall impact.","FDA warning letter (July 17, 2023) for Boston facility quality systems; does not restrict shipping but requires annual third-party audit for three years.","Planning $125M share repurchase in Q3 under new $225M board authorization; replaced prior program.","Updated FY2023 guidance: revenue $1.548-1.560B, adj EPS $3.10-3.18; Boston restart late Q4'23, commercial distribution mid-Q2'24."],"urls":{"canonical":"https://secwatch.observer/filing/0000917520-23-000060","json":"https://secwatch.observer/filing/0000917520-23-000060.json","markdown":"https://secwatch.observer/filing/0000917520-23-000060.md","text":"https://secwatch.observer/filing/0000917520-23-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000060/0000917520-23-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000060/iart-20230726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T01:56:47.963352+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02cd4d1cfdd4d30d02a8be69bc5b4448b48212f3","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP reported the quarter ended June 30, 2023 results: revenue $381.3 million, net income $4.2 million, EPS $0.05 per diluted share.","evidence_excerpt":"Total reported revenues of $381.3 million declined 4.2% on a reported basis and declined 2.7% on an organic basis compared to the prior year. The Company reported GAAP gross margin of 54.3%, compared to 62.7% in the second quarter of 2022. Adjusted gross margin was 67.6%, compared to 68.0% in the prior year. Adjusted EBITDA for the second quarter of 2023 was $88.8 million, or 23.3% of revenue, compared to $102.8 million, or 25.8% of revenue, in the prior year. The Company reported GAAP net income of $4.2 million, or $0.05 per diluted share, in the second quarter of 2023, compared to a GAAP net income of $44.8 million, or $0.54 per diluted share, in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000060/0000917520-23-000060-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$381.3 million"},{"label":"Net income","value":"$4.2 million"},{"label":"EPS","value":"$0.05 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6519effe9943e51169f6a4bded8d3edb0e3acb17","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP reported full year 2023 results: revenue $1.548 billion to $1.560 billion, EPS $3.10 to $3.18.","evidence_excerpt":"Updating full-year 2023 revenue and adjusted earnings per share guidance with a range of $1.548 billion to $1.560 billion and $3.10 to $3.18 respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000060/0000917520-23-000060-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$1.548 billion to $1.560 billion"},{"label":"EPS","value":"$3.10 to $3.18"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"7e36e23826bf0945d9dda357981578f68ed6b7d6","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP reported the third quarter 2023 results: revenue $386 million to $390 million, EPS $0.76 to $0.80.","evidence_excerpt":"For the third quarter 2023, the Company expects reported revenues in the range of $386 million to $390 million, representing reported growth of 0.2% to 1.3 % and organic growth of 0.3% to 1.3 % . Adjusted earnings per diluted share are expected to be in the range of $0.76 to $0.80","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000060/0000917520-23-000060-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter 2023"},{"label":"Revenue","value":"$386 million to $390 million"},{"label":"EPS","value":"$0.76 to $0.80"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}